Two-Decade Old US Interstate Compounding Provision Stayed For More Comments
Executive Summary
Responding to court ruling, US FDA will explore what it will cost compounding pharmacies to submit to increased state restrictions and oversight of out-of-state compounding quality under a standard MOU that Congress required decades ago.
You may also be interested in...
US FDA Must Assess Business Impact Of Final Interstate Compounding MOU, Court Rules
Summary judgment puts 20-year-old effort to define ‘inordinate’ out-of-state drug compounding back on slow track.
US FDA Training Up Inspectorate To Oversee Quality Of Novel Manufacturing Technologies
Agency is hiring contractor to identify gaps in the ability of inspectors, investigators and compliance officers to oversee manufacturing quality in the context of new and emerging technologies – and to identify organizations that could fill the gaps through training.